Latest On Five Prime Therapeutics, Inc (FPRX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-04-16 13:31 EST | News | Amgen completes $1.9B acquisition of Five Prime Therapeutics | N/A |  |
| 2021-03-13 00:56 EST | News | Five Prime Is Acquired By Amgen In A Shareholder-Friendly Deal | N/A | |
| 2021-03-09 07:44 EST | Analyst Rating | The Analyst Target Price has increased from $35.67 to $37.17. | Neutral | |
| 2021-03-05 07:47 EST | Analyst Rating | The Analyst Target Price has increased from $27.29 to $35.67. | Neutral | |
| 2021-03-04 22:25 EST | News | Amgen to acquire Five Prime Therapeutics for $1.9B | N/A | |
About Five Prime Therapeutics, Inc (FPRX):
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia read more.../Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
General
- Name Five Prime Therapeutics, Inc
- Symbol FPRX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 87
- Fiscal Year EndDecember
- IPO Date2013-09-18
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.fiveprime.com
Valuation
- Price/Sales (Trailing 12 Mt.) 78.32
- Price/Book (Most Recent Quarter) 18.27
- Enterprise Value Revenue 97.98
- Enterprise Value EBITDA 0.03
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.59
- Operating Margin -513%
- Return on Assets -26%
- Return on Equity -69%
- Revenue 17.1 million
- Earnings Per Share -$4.49
- Revenue Per Share $0.48
- Gross Profit -92976000
- Quarterly Earnings Growth -31.4%
Highlights
- Market Capitalization 1.73 billion
- EBITDA -154670000
- PEG Ratio 0.14
- Analyst Target Price $37.17
- Book Value Per Share $2.67
Share Statistics
- Shares Outstanding 45.94 million
- Shares Float 20.78 million
- % Held by Insiders 319%
- % Held by Institutions 47.1%
- Shares Short 2.85 million
- Shares Short Prior Month 2.58 million
- Short Ratio 3.24
- Short % of Float 8%
- Short % of Shares Outstanding 6%
Technicals
- Beta 4.47
- 52 Week High $38.9
- 52 Week Low $1.95
- 50 Day Moving Average 25.42
- 200 Day Moving Average 14.87
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Five Prime Therapeutics, Inc (FPRX) Dividend Calendar:
Five Prime Therapeutics, Inc (FPRX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Five Prime Therapeutics, Inc (FPRX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Five Prime Therapeutics, Inc (FPRX) Chart:
Five Prime Therapeutics, Inc (FPRX) News:
Below you will find a list of latest news for Five Prime Therapeutics, Inc (FPRX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Five Prime Therapeutics, Inc (FPRX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Five Prime Therapeutics, Inc (FPRX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-03 | 8-K (Current report) | |
| 2020-11-03 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-02 | 8-K (Current report) | |
| 2020-10-08 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-10-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-04 | 8-K (Current report) | |
| 2020-09-01 | 8-K (Current report) | |
| 2020-08-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-06 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-05 | CT ORDER (Confidential treatment order) | |
| 2020-08-03 | CT ORDER (Confidential treatment order) | |
| 2020-05-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-20 | 8-K (Current report) | |
| 2020-05-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-18 | 3 (Initial statement of beneficial ownership of securities) | |
Five Prime Therapeutics, Inc (FPRX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Five Prime Therapeutics, Inc (FPRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 319%
Institutional Ownership: 4710%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-06 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 10,436.00 | 4.98 | 52,013.02 | 3,434,990.00 | |
| 2020-11-06 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 17,230.00 | 4.98 | 85,874.32 | 4,611,909.00 | |
| 2020-11-06 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 2,334.00 | 4.98 | 11,632.66 | 583,912.00 | |
| 2020-11-04 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 143,403.00 | 4.88 | 700,408.93 | 3,424,554.00 | |
| 2020-11-04 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 257,804.00 | 4.88 | 1,259,166.30 | 4,594,679.00 | |
| 2020-11-04 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 15,355.00 | 4.88 | 74,996.89 | 581,578.00 | |
| 2020-10-06 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 162,352.00 | 5.04 | 817,442.32 | 3,281,151.00 | |
| 2020-10-06 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 157,782.00 | 5.04 | 794,432.37 | 4,336,875.00 | |
| 2020-10-06 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 25,107.00 | 5.04 | 126,413.75 | 566,223.00 | |
| 2020-09-22 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 32.00 | 3.80 | 121.56 | 541,116.00 | |
| 2020-05-14 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 39,810.00 | 4.10 | 163,221.00 | 3,118,799.00 | |
| 2020-05-14 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 249,301.00 | 4.10 | 1,022,134.10 | 4,179,093.00 | |
| 2020-05-14 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 4,476.00 | 4.10 | 18,351.60 | 541,084.00 | |
| 2020-04-13 | Thomas Civik | President and CEO | Buy | 75,000.00 | 75,000.00 | | ||
| 2020-02-24 | Francis Willard Sarena | Chief Strategy Officer | Buy | 15,000.00 | 108,178.00 | | ||
| 2020-02-24 | David White | Officer | Buy | 10,000.00 | 45,000.00 | | ||
| 2020-02-24 | David V Smith | Executive Vice President & CFO | Buy | 15,000.00 | 48,389.00 | | ||
| 2020-02-24 | Helen Louise Collins | EVP and Chief Medical Officer | Buy | 15,000.00 | 53,953.00 | | ||
| 2020-02-24 | David V Smith | Executive Vice President & CFO | Buy | 15,000.00 | 63,389.00 | | ||
| 2020-02-24 | Helen Louise Collins | EVP and Chief Medical Officer | Buy | 15,000.00 | 68,953.00 | |